TGFB1 and prostate carcinoma: All patients exhibited a sharp decrease in plasma TGF-β1 level postoperatively, reaching minimum values regarding POD1 for breast and colorectal cancer patients (Figure 11B,C) and POD2 for prostate cancer patients (Figure 11D) before returning to baseline within one week.